Pakistani Drugmaker Achieves Second WHO Prequalification for Manufacturing Site

KARACHI: A Pakistani pharmaceutical company has achieved a significant milestone by securing World Health Organization (WHO) prequalification for its Astola manufacturing facility, announced on November 2, 2026. This marks the second production site of the company to receive this prestigious international certification, underscoring its commitment to quality and safety in drug manufacturing.

The WHO prequalification is a rigorous process that evaluates the quality, safety, and efficacy of medicines. This certification allows the company to expand its market reach and supply essential medicines to various countries, particularly in regions where access to quality healthcare is limited. An official from the company stated, “This achievement reflects our dedication to meeting global health standards and enhancing the availability of affordable medicines worldwide.”

The implications of this prequalification are profound for both the local economy and public health. It not only boosts the company’s reputation but also positions Pakistan as a growing player in the global pharmaceutical market. This development is expected to attract foreign investment and create job opportunities, contributing to the overall economic growth of the region.

Looking ahead, the company plans to leverage this certification to explore new partnerships and expand its product line. Upcoming initiatives include participation in international health conferences and collaborations with global health organizations to further enhance its manufacturing capabilities and product offerings.